Managed access programmes of the type overseen by Idis allow doctors to request unlicensed therapies for patients.
It’s often used as a way of making treatments available to people who have run out of options or were unable to take part in the clinical studies, but who may benefit from access to the treatment.
People will gain access in Europe Diurnal’s Infacort for paediatric patients with adrenal insufficiency and Chronocort to treat patients with congenital adrenal hyperplasia.
"The effective treatment of patients with CAH and paediatric AI represents a significant unmet need,” said Steve Glass, Clinigen’s chief commercial officer in North America and Europe.
“As the global leader in providing managed access programmes, we can leverage our international reach to support these patients by enabling their physicians to access these therapies safely, ethically and quickly, ahead of approval and launch."